Research Parks Forming Strategies To Adapt To End Of Building-Boom

Of Building Boom Faced with decreased federal funding and corporate cuts in R&D, science complexes turn to economic development and incubation for help. 'GOOD NEWS': University Park at Southern Illinois University has seen small companies blossom. Research parks, like other facilities that house working scientists, are facing some new economic realities. Growth has slowed since the mid-1990s, government funding of research is down, and corporate tenants are looking to please Wall Street i

Written byThomas Durso
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Of Building Boom Faced with decreased federal funding and corporate cuts in R&D, science complexes turn to economic development and incubation for help.


'GOOD NEWS': University Park at Southern Illinois University has seen small companies blossom.
Research parks, like other facilities that house working scientists, are facing some new economic realities. Growth has slowed since the mid-1990s, government funding of research is down, and corporate tenants are looking to please Wall Street investors by slashing staff. These challenges are making one thing clear to park administrators: Economic viability depends on finding new ways of doing business.

"If the research itself is going down, who's going to want a research park?" says Louis Padulo, president and chief executive officer of Philadelphia's University City Science Center, the home of 140 tenants (including The Scientist). "What are you going to do with a research park?"

Park administrators are exploring several ways to stay ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies